CF PharmTech is a technology company.
CF PharmTech has raised $51.0M across 1 funding round.
CF PharmTech has raised $51.0M in total across 1 funding round.
CF PharmTech is a fully integrated specialty pharmaceutical company focused on the research, development, manufacturing, and commercialization of inhalation products for respiratory diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD), respiratory infections, pulmonary fibrosis, and pulmonary hypertension.[1][2][3] It serves patients and healthcare providers in the international market by addressing high clinical needs in these areas through innovative drug products, with a pipeline featuring small molecule drugs, siRNA therapies, and candidates like TRN-157 (M3 receptor agonist in Phase 2 for pulmonary emphysema) and CP029 (preclinical for asthma).[2][4]
The company demonstrates growth momentum via an active pipeline with 19 clinical trials, recent initiations (e.g., trials starting in June 2025, October 2024, and September 2024), and a focus on international expansion from its origins in China.[3][4]
CF PharmTech was founded in 2007 in Jiangsu Province, China, evolving from a regional player into a professional pharmaceutical company targeting the international market with integrated R&D, production, and sales capabilities in respiratory diseases.[3] While specific founder details are not publicly detailed in available sources, the company's early emphasis on respiratory therapeutics laid the groundwork for its specialization, leading to pivotal advancements like a diversified pipeline including Phase 2 assets and ongoing clinical trials.[1][4]
CF PharmTech rides the global trend of rising respiratory disease prevalence, driven by aging populations, pollution, and post-pandemic awareness of lung health, where inhalation therapies offer precise delivery for conditions like COPD and asthma.[2] Timing aligns with advances in targeted biologics and small molecules for respiratory unmet needs, bolstered by market forces such as increasing demand for innovative inhalers amid generic competition erosion.[1][4] It influences the ecosystem by contributing to China's biopharma export growth, advancing clinical data that could shape treatment standards, and fostering international partnerships through its pipeline progress.[3][4]
CF PharmTech is poised for expansion with Phase 2 readouts from TRN-157 and preclinical advancements, potentially unlocking partnerships or approvals in major markets.[4] Trends like AI-driven drug discovery, personalized inhalers, and global respiratory health investments will shape its path, amplifying its influence from a China-based innovator to a key respiratory player. This builds on its integrated model, targeting sustained growth in high-need therapeutics.[2][3]
CF PharmTech has raised $51.0M in total across 1 funding round.
CF PharmTech's investors include BioTrack Capital.
CF PharmTech has raised $51.0M across 1 funding round. Most recently, it raised $51.0M Series F in June 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2020 | $51.0M Series F | BioTrack Capital |